Dexborneol

Summary

Dexborneol (CHEMBL486208) is a phase-3 clinical-stage small molecule targeting TRPV3; indicated across 2 conditions including stroke disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (TRPV3)
• Indications: 2 conditions
• Clinical trials: 12
• Chemistry: 154.25 Da · C10H18O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL486208
Name	Dexborneol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6552009
ChEBI	CHEBI:15393
Molecular formula	C10H18O
Molecular weight	154.25
InChIKey	DTGKSKDOIYIVQL-WEDXCCLWSA-N

SMILES: C[C@@]12CC[C@@H](C1(C)C)C[C@@H]2O

IUPAC name: (1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol

Also known as: (-) borneol, Borneol d-form, Borneol, d-, D-borneol, D-camphanol, Dexborneol, FEMA NO. 2157, (+)-, DEXBORNEOL

Patent coverage: 38,240 distinct patent families (61,592 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 61,591 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TRPV3	TRPV3	Activation	2.46	0%	Q8NET8

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): TRPV3.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
TRP channels	1	TRPV3

Dominant GO biological processes

GO term	Targets
actin filament organization	1
osmosensory signaling pathway	1
response to temperature stimulus	1
negative regulation of hair cycle	1
calcium ion transmembrane transport	1
positive regulation of calcium ion import	1
calcium ion import across plasma membrane	1
monoatomic ion transport	1
calcium ion transport	1
monoatomic ion transmembrane transport	1
sodium ion transmembrane transport	1
transmembrane transport	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
stroke disorder	3	MONDO:0005098	EFO:0000712

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE2	4
PHASE4	3
PHASE3	3
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06645522	PHASE4	NOT_YET_RECRUITING	Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke
NCT07454473	PHASE4	RECRUITING	Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study
NCT06248242	PHASE4	UNKNOWN	Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol
NCT04950920	PHASE3	COMPLETED	Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke
NCT05249920	PHASE3	COMPLETED	Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)
NCT05885919	PHASE3	UNKNOWN	Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke
NCT04667637	PHASE2	COMPLETED	Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol
NCT04714177	PHASE2	UNKNOWN	Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage
NCT04817527	PHASE2	UNKNOWN	Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows
NCT05035953	PHASE2	UNKNOWN	Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke
NCT05121883	Not specified	UNKNOWN	Edaravone Dexborneol Combining With Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke
NCT05644223	Not specified	UNKNOWN	Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

5 molecules share ≥1 primary target. Top 5 by shared-target count:

Molecule	Source	Status	Shared targets
CANNABINOL	ChEMBL	Phase 3	TRPV3
CANNABIDIVARIN	ChEMBL	Phase 2	TRPV3
CANNABIGEROL	ChEMBL	Phase 2	TRPV3
TETRAHYDROCANNABIVARIN	ChEMBL	Phase 2	TRPV3
camphor (synthetic)	PubChem	Approved	TRPV3